Vaccine Therapy for Patients With Stage IV Melanoma
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00052156|
Recruitment Status : Unknown
Verified April 2005 by CancerVax Corporation.
Recruitment status was: Active, not recruiting
First Posted : January 24, 2003
Last Update Posted : June 24, 2005
|Condition or disease||Intervention/treatment||Phase|
|Malignant Melanoma||Biological: CancerVax vaccine (CANVAXIN)||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||670 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||A Phase III Randomized Double-Blind Pivotal Trial of Immunotherapy With a Polyvalent Melanoma Vaccine, CancerVax™ Vaccine Plus BCG Versus Placebo Plus BCG as a Post-Surgical Treatment for Stage IV Melanoma|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00052156